Key Takeaways
- • LifeStance Health (LFST) stock has roughly doubled in value this year, outpacing telehealth peers Teladoc Health (TDOC), Hims & Hers Health (HIMS) and Doximity (DOCS), according to Investor's Business Daily.
- • The behavioral health services company was built rollup-style through about 100 acquisitions with private-equity backing, and is now posting double-digit revenue growth and clinician additions.
- • Part of the company's growth is now organic rather than acquisition-driven, though the source article does not quantify the organic contribution in the excerpt available.
- • Analysts foresee significant earnings growth, but one analyst cautioned that "the bar is higher" for the stock following its rally.
Summary
The behavioral health services provider was assembled through a rollup strategy, completing about 100 acquisitions with private-equity backing. That model has translated into double-digit revenue growth and continued additions to its clinician base, with the company now showing some organic growth alongside its acquisitive expansion. The article's excerpt does not provide specific revenue, earnings or clinician-count figures.
Analysts expect substantial earnings growth ahead, per the publication's summary. However, the expectations bar has risen with the stock's rally, a point one analyst made explicitly. For institutional investors, the story frames LifeStance as a case where a private-equity rollup has transitioned into a stock valued partly on organic growth, making the sustainability of that growth the central question.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.